Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.46 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 8/20 | 0.37 |
| ▸ | CA2 | P00918 | 8/20 | 0.37 |
| ▸ | CA4 | P22748 | 8/20 | 0.37 |
| ▸ | CA9 | Q16790 | 8/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13340969 | 0.93 | ABHD6 (0.44) | ABHD6DAGLAPARP1DPP4NR1H2 | |
| SCHEMBL13340972 | 0.91 | ABHD6 (0.43) | ABHD6DAGLAPARP1DPP4NR1H2 | |
| SCHEMBL13340974 | 0.91 | ABHD6 (0.47) | ABHD6DAGLAPARP1DPP4NR1H2 | |
| SCHEMBL8230166 | 0.88 | ABHD6 (0.46) | ABHD6DAGLAPARP1DPP4NR1H2 | |
| SCHEMBL8230011 | 0.88 | ABHD6 (0.46) | ABHD6DAGLAPARP1DPP4NR1H2 | |
| SCHEMBL8235524 | 0.88 | ABHD6 (0.46) | ABHD6DAGLAPARP1DPP4NR1H2 | |
| SCHEMBL13340957 | 0.87 | ABHD6 (0.44) | ABHD6DAGLAPARP1DPP4NR1H2 | |
| SCHEMBL8238428 | 0.87 | ABHD6 (0.44) | ABHD6DAGLAPARP1DPP4NR1H2 | |
| SCHEMBL8236084 | 0.86 | ABHD6 (0.45) | ABHD6DAGLAPARP1DPP4NR1H2 | |
| SCHEMBL8239114 | 0.86 | ABHD6 (0.43) | ABHD6DAGLAPARP1DPP4NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-13 | — | — | US | disclosed |
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | REN, AGTR1, AGTR2 | ABHD6 2780/4885DAGLA 4388/4885PARP1 2353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.